Who we are
The roots of ALK can be traced back to 1923. Since then, we have been working to improve quality of life for allergy patients whose disease can severely affect their quality of life.
The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK is headquartered in Denmark and listed on NASDAQ Copenhagen (OMX: ALK B).
What we do
As a world leader in allergy immunotherapy, we work to improve quality of life for the many allergy sufferers whose disease remains uncontrolled despite the use of symptom-relieving medication, by developing products that provide long-lasting relief.
ALK offers allergy immunotherapy products in the form of injections, sublingual drops and sublingual tablets – the latter is the newest, most documented and most convenient form of treatment.
In addition, ALK also produces an adrenaline auto-injector for the treatment of severe allergic reactions (anaphylaxis) and also manufactures products used in the diagnosis of allergies.
Why we care
Allergic disease is one of the world’s most common chronic conditions, affecting millions of people globally. Hay fever (allergic rhinitis) alone affects an estimated 400-500 million people worldwide, approximately 10% of whom experience a debilitating form of their condition. Left untreated, allergic rhinitis is considered to be a major risk for the development of asthma.
Allergy also imposes a significant cost on society, through lower productivity, increased sick leave, as well as significant healthcare costs. For example, a study from the USA has shown that allergic rhinitis causes a greater loss of annual productivity than either stress, migraine, depression, arthritis/rheumatism, anxiety disorder, respiratory infections, hypertension/high blood pressure, diabetes, asthma, or coronary heart disease.
As a treatment concept, allergy immunotherapy is now more than 100 years old. As a constant pioneer in the field, we have challenged and pushed the boundaries of allergy treatment so that, today, allergy immunotherapy is entering a new era of evidence-based treatment following the advent of more convenient tablet-based treatments.